We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




High-Throughput Micro-Aperture Chip System Detects Cancer Cells

By LabMedica International staff writers
Posted on 24 Oct 2013
A system is being developed that uses tiny magnetic beads to quickly detect rare types of cancer cells circulating in a patient's blood. More...


The microchip system is based on a combination of immunomagnetic separation and microfluidics for high-throughput detection of whole cells and in this system target cells bound to magnetic beads flow parallel to a microchip.

Scientists at Purdue University (West Lafayette, IN, USA) combined the two techniques of immunomagnetic separation and microfluidics. In immunomagnetic separation, magnetic beads about a micron in diameter are "functionalized," or coated with antibodies that recognize and attach to antigens on the surface of target cells. The functionalized beads recognize breast cancer and lung cancer cells in laboratory cultures.

The updated design passes the fluid through a chamber that allows for faster flow; a standard 7.5 mL fluid sample can run through the system in a matter of minutes. The beads are directed by a magnetic field to a silicon mesh containing holes 8 µm in diameter. Because the target cells are so sparse, many of the beads fail to attract any and pass through the silicon mesh. The beads that have attached to cells are too large to pass through the holes in the mesh.

The cells can be analyzed clearly under a microscope and released from the chip for further analysis by removing the magnetic field. The system was characterized by detecting human breast adenocarcinoma cell line (MCF-7) and adenocarcinomic human alveolar basal epithelial cells (A549) in culture media using anti- epithelial cell adhesion molecule (EpCAM) conjugated magnetic beads.

Cagri A. Savran, PhD, an associate professor of Biomedical Engineering at Purdue, said, “We were able to detect cancer cells with up to a 90% yield. We expect this system to be useful in a wide variety of settings, including detection of rare cells for clinical applications. What's new here is that we've built a system that can perform all of these steps on one chip. It both separates cells and also places them on a chip surface so you can count them and study them with a microscope.” The study was highlighted on September 18, 2013, in the journal Lab on a Chip.

Related Links:

Purdue University



New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Gold Member
Aspiration System
VACUSAFE
New
Thyroid Test
Anti-Thyroid EIA Test
New
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.